Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient.
We report here a very rare case of a nephrotic patient who developed acute myelogenous leukemia (AML, M2) 8 months after receiving cyclosporin A (CsA) therapy. A 30-year-old man with nephrotic syndrome had been taking diphenylhydantoin (DPH, 300 mg/day) for 6 years for treatment of convulsion and then received treatment of prednisolone and CsA (75 mg/day) for a nephrotic syndrome. Approximately 4 months after CsA therapy began, myeloblasts appeared in his peripheral blood at a ratio of 1%. Four months later, bone marrow aspiration and a biopsy confirmed a diagnosis of AML M2, showing hypercellular bone marrow with 60% leukemic cells. He received induction chemotherapy, which led to a complete remission.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016572:Cyclosporine / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003561:Cytarabine; D016572:Cyclosporine; C015019:enocitabine; D003630:Daunorubicin